Analyst Conference Summaries

Biotechnology Investor Aids

Reata Pharmaceuticals

conference date: May 9, 2019 @ 5:00 AM Pacific Time

Reata Bardoxolone Trial Success Likely, But Still Just A Hold [May 24, 2019 at Seeking Alpha]

Reata Pharmaceuticals a Buy [Feb. 14, 2018 at Seeking Alpha]

Q4 2018
Q1 2019
Feb. 28, 2019 May 9, 2019    
March 2, 2018
May 9, 2018
August 8, 2018
Nov. 7, 2018

Reata Pharmaceuticals (RETA) is a clinical-stage biotechnology company specializing in therapies to improve mitochondrial functions for rate diseases, including chronic kidney diseases.

Reata Pharmaceutical web site



More Analyst Conference Pages:


Disclaimer: My analyst summaries may include both condensations of statements made by company representatives and my own analysis. They are not covered by any warranty. I cannot guarantee anything said by company representatives is true. I try not to make errors, but it is possible. These are my personal notes which I share with other investors and which I use as the basis of my blog and Seeking Alpha articles.

Copyright 2019 William P. Meyers